News

Actelion has reported that the selective S1P1 receptor agonist ACT-128800/ RG3477 has achieved an important clinical milestone. Actelion’s selective S1P1 (Sphingosine-1-phosphate) receptor agonist has entered into a phase

MediGene has completed patient enrollment in its randomised phase II trial of EndoTAG-1, for the treatment of triple receptor-negative breast cancer. Results will be available as scheduled in

Lid Hair Studios has completed its reverse merger with Shaanxi Jiali Pharmaceuticals (Shaanxi Jiali). Concurrent, the company has appointed the following Officers and Directors: Jun Xia as president,

Vivante GMP Solutions (Vivante) has completed process optimisation activities related to the upcoming production of a GMP clinical lot of an Oxford University adenovirus-based malaria vaccine. Reportedly, the

Locus Pharmaceuticals (Locus) has entered into a research collaboration with Novartis. As per the deal, Locus will collaborate with Novartis to discover novel chemotypes on targets of interest

Cornerstone Pharmaceuticals (Cornerstone) has included cancer research scientist, Robert Weinberg, a founding member of the Whitehead Institute for Biomedical Research and a Professor of Biology at MIT, in

Biomet has reported an increase in net sales by 4% to $630.1m for the first quarter ended August 31,2009, compared to $607m for the same period prior year.

Purdue Pharma is working with the FDA for the development of a new version its OxyContin pain medication. It has met with the Joint FDA Advisory Committee for

BioGaia has entered into an agreement with Pharma Nord, which gives Pharma Nord exclusive rights to sell BioGaia’s Probiotic tablets and drops in Denmark. Reportedly, BioGaia’s probiotic products